SpringWorks Therapeutics Announces Issuance of New U.S. Composition of Matter Patent to Polymorphic Form of Nirogacestat, Extending Patent Protection into 2039

NEXT STORY
VAXART ANNOUNCES IT ENTERED INTO AN AGREEMENT WITH EMERGENT BIOSOLUTIONS FOR THE DEVELOPMENT AND MANUFACTURING OF ORAL CORONAVIRUS (COVID-19) VACCINE CANDIDATE
PREV STORY
ASLAN Pharmaceuticals Reports Fourth Quarter and Full Year 2019 Financial Results and Provides Corporate Update
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

GSK signs strategic agreement to transfer rare disease gene therapy portfolio to Orchard Therapeutics

author_avatar
NASDAQ Market News

Poseida Therapeutics Appoints Two Independent Directors, Adding Leaders for Compensation and Governance Functions

SAN DIEGO, Jan. 04, 2019 (GLOBE NEWSWIRE) -- Poseida Therapeutics Inc., a clinical-stage biopharmaceutical ...

author_avatar
NASDAQ Market News

Global Ambulatory IV Infusion Pumps Market Overview By The Business Research Company

author_avatar
NASDAQ Market News